ClinicalTrials.gg
CompletedNCT05144139Updated Dec 28, 2022

A Phase I/II Clinical Trial in Healthy People Aged 18 Years and Above

A Phase 1/2 interventional study of COVID-19 mRNA vaccine in COVID-19 Pandemic, sponsored by Stemirna Therapeutics. Completed at 1 site in Lao People's Democratic Republic. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-12-28.

Sponsored by Stemirna Therapeutics · Phase 1/2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
480
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing mRNA COVID-19 Vaccine in COVID-19 — 3 open to participants now, 3 under way, none of them phase 3. mRNA COVID-19 Vaccine · COVID-19.

Enrollment
3rd of 12
480 · median 157
Started
2021
with 4 others
Phase 1/2
2 of 12
1 open now
Registered
5th of 12
by date
Lead sponsor
1 of 12
Stemirna Therapeutics

Among the 12 studies testing mRNA COVID-19 Vaccine in COVID-19, this one is the 3rd largest by enrollment, is one of 5 that started in 2021, is one of 2 in phase 1/2, and was the 5th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

3 of the 12 studies testing mRNA COVID-19 Vaccine in COVID-19 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About mRNA COVID-19 Vaccine

mRNA COVID-19 Vaccine: first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing mRNA COVID-19 Vaccine in COVID-19, or all of them as a file.
02

Study summary

This clinical trial is a phase I/II clinical trial to evaluate the safety, immunogenicity and immune persistence of COVID-19 mRNA vaccine in healthy people aged 18 years and above.

Read the detailed description

This is the clinical trial including an open-label, single-arm Phase I study and a subsequent randomized, blind, placebo-parallel controlled Phase II study to evaluate the safety, immunogenicity and immune persistence of COVID-19 mRNA vaccine in healthy people aged 18-60 years and ≥18 years respectively, whose locations or circumstances put them at appreciable risk of acquiring COVID-19 and/or SARS-CoV-2 infection.

03

Conditions studied

  • COVID-19 Pandemic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • People aged 18-60 years (both inclusive) for phase 1 and aged ≥18 years for phase 2;
  • Medical history and physical examination indicating as a healthy person;
  • The female participant or the spouse (or partner) of the male participant in child-birthing age agrees to use effective measure throughout the whole course of this clinical trial.
  • Those who are participating in this clinical trial voluntarily, have signed the form, and been able to understand and comply with the requirements of the clinical trial protocol.

Exclusion criteria

Exclusion Criteria:

  • Confirmed cases or history of SARS-CoV-2 infection;
  • Has a history of SARS and MERS virus infection;
  • Has fever (axillary temperature ≥37.3℃), dry cough, fatigue, nasal congestion, runny nose, sore throat, myalgia, diarrhea, shortness of breath, and dyspnea within 14 days before vaccination;
  • Positive urine pregnancy test;
  • Axillary temperature ≥37.3℃ at the day vaccinated;
  • History of severe allergic reactions to vaccination (such as acute allergic reactions, urticaria, dyspnea, angioneurosis, edema, etc.) or allergies to known components of COVID-19 mRNA vaccine;
  • History or family history of convulsions, epilepsy, encephalopathy, or mental illness;
  • Suffering from congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.;
  • Known suffering from diseases including: acute respiratory disease (such as flu-like illness, acute cough, sore throat), severe cardiovascular disease, kidney disease, uncontrolled hypertension (systolic blood pressure >150 mmHg, diastolic blood pressure >90 mmHg), diabetes complications, malignant tumor, all sorts of acute illness or chronic diseases acute phase;
  • Diagnosis with congenital or acquired immunodeficiency, infection, lymphoma, leukemia, or other disease;
  • Abnormal coagulation function (such as lack of coagulation factor, coagulation disorders);
  • Receiving anti-tuberculosis treatment;
  • Long-term receipt (continuous≥7 days) of (reverence value for dose: amount to≥20 mg/d prednisone equivalent), except inhaled, topical, nasal, aural and ophthalmic corticosteroids, within 6 months before screening; Receipt of immunotherapy or within 3 months (continuous oral or infusion for more than 14 days);
  • Receipt of within 28 days prior to vaccination and other vaccines within 14 days prior to vaccination;
  • Receipt of blood products within 3 months prior to vaccination
  • Receipt of other study drugs within 6 months prior to vaccination;
  • Receipt of any SARS-COV-2 vaccine;
  • Other situations judged by the investigators that are not suitable for participating in this clinical trial.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
480 participants (actual)

Study arms

  • Experimental
    Low dose group with mRNA vaccine

    25μg with COVID-19 mRNA vaccine

    Biological: COVID-19 mRNA vaccine

  • Placebo comparator
    Low dose group with placebo

    Low dose group with placebo

    Biological: COVID-19 mRNA vaccine

  • Experimental
    High dose group with mRNA vaccine

    45μg with COVID-19 mRNA vaccine

    Biological: COVID-19 mRNA vaccine

  • Placebo comparator
    High dose group with placebo

    High dose group with placebo

    Biological: COVID-19 mRNA vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. local/systemic solicited adverse reaction/events

    The incidence of local/systemic solicited adverse reaction/events

    Time frame: up to 6 days after each dose

  2. unsolicited adverse events

    The incidence of unsolicited adverse events

    Time frame: up to 21 days and up to 28 days after the first and second dose of immunization, respectively

  3. The incidence of SAE

    The incidence of SAE from the first dose of vaccination to 28 days after the full course of immunization

    Time frame: up to 28 days after the full course of immunization

Secondary outcomes

  1. The seroconversion rate, 2-fold or 4-fold rise and GMT/GMI of the SARS-COV-2 S-protein specific antibody (specific total antibody/IgG antibody) and neutralizing antibody

    The seroconversion rate, 2-fold or 4-fold rise and GMT/GMI of the SARS-COV-2 S-protein specific antibody (specific total antibody/IgG antibody) and neutralizing antibody 14 days after the full immunization in the subjects who take two doses as protocol specified

    Time frame: 14 days after the full immunization

  2. The incidence of SAE

    The incidence of SAE within the 29th \~365th day after the full course of immunization

    Time frame: the 29th ~365th day after the full course of immunization

  3. Changes in laboratory abnormal parameters

    Changes in laboratory abnormal parameters in the participants who take at least of one dose

    Time frame: after at least of one dose

Other outcomes

  1. The positive conversion rate, 2-fold or 4-fold rise and GMT/GMI of the SARS-COV-2 S-protein specific antibody (specific total antibody/IgG antibody), neutralizing antibody

    The positive conversion rate, 2-fold or 4-fold rise and GMT/GMI of the SARS-COV-2 S-protein specific antibody (specific total antibody/IgG antibody), neutralizing antibody before 1st and 2nd immunization, 90, 180, 365 days after the full immunization

    Time frame: before 1st and 2nd immunization, 90, 180, 365 days after the full immunization

  2. Cellular immunity INF-γ, IL-4 and IL-2

    Cellular immunity (INF-γ, IL-4 and IL-2) before 1st and 2nd immunization, and 14, 90, 180, 365 days after the full immunization

    Time frame: before 1st and 2nd immunization, and 14, 90, 180, 365 days after the full immunization

07

Study locations

1 site
  • Mayfong Mayxay
    Vientiane, 01000, Lao People's Democratic Republic
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Aug 2022, 8 months.

Of 80 industry-sponsored phase 1/2 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 8 months is below that.

Counting every sponsor, half of 187 studies reached it within 11 months; a quarter within 4 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2021
First posted
Dec 3, 2021
StartActual
Dec 3, 2021
Primary completionActual
Aug 28, 2022
CompletionActual
Nov 11, 2022
Last update
Dec 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05144139
Lead sponsor
Stemirna Therapeutics
Responsible party
Sponsor
First posted
Dec 3, 2021
Start date
Dec 3, 2021
Primary completion
Aug 28, 2022
Completion
Nov 11, 2022
Last update
Dec 28, 2022

Study contacts

Mayfong Mayxay, professor
principal investigator · Mahosot Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: mRNA COVID-19 Vaccine

Start the discussion